https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):9
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2025-01-23 / J Hematol Oncol 2025 Jan;18(1):92025-01-23 00:00:002025-01-23 00:00:00WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-12-17 / Cancers (Basel) 2024 Dec;16(24)2024-12-17 00:00:002024-12-17 00:00:00Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-10-29 / Int Immunopharmacol 2024 Dec;143(Pt 2):113481
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-10-29 / Int Immunopharmacol 2024 Dec;143(Pt 2):1134812024-10-29 00:00:002024-10-29 00:00:00Synergistic Anti-Tumor Effects of Newcastle Disease Virus and Doxorubicin: Evidence from A Murine Breast Cancer Model
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-08-30 / Front Mol Biosci 2024;11:1331369
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-08-30 / Front Mol Biosci 2024;11:13313692024-08-30 00:00:002024-08-30 00:00:00Antimetastatic and antitumor activities of oncolytic NDV AMHA1 in a 3D culture model of breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-04-09 / Med Oncol 2024 Apr;41(5):112
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-04-09 / Med Oncol 2024 Apr;41(5):1122024-04-09 00:00:002024-04-09 00:00:00Recent developments in targeting breast cancer stem cells (BCSCs): a descriptive review of therapeutic strategies and emerging therapies
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-03-21 / Front Immunol 2024;15:1375433
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-03-21 / Front Immunol 2024;15:13754332024-03-21 00:00:002024-03-21 00:00:00New hopes for the breast cancer treatment: perspectives on the oncolytic virus therapy
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2024-02-01 / Cancer Lett 2024 Mar;585:216634
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2024-02-01 / Cancer Lett 2024 Mar;585:2166342024-02-01 00:00:002024-02-01 00:00:00Oncolytic virus-based combination therapy in breast cancer
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-12-26 / Mol Aspects Med 2024 Feb;95:101239
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-12-26 / Mol Aspects Med 2024 Feb;95:1012392023-12-26 00:00:002024-01-30 12:49:47Reviewing the significance of dendritic cell vaccines in interrupting breast cancer development
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-09-01 / Clin Exp Med 2023 Dec;23(8):4431-4447
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-09-01 / Clin Exp Med 2023 Dec;23(8):4431-44472023-09-01 00:00:002023-09-01 00:00:00Breast cancer immunotherapy: a comprehensive review
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2023-07-15 / J Immunol 2023 Jul;211(2):219-228
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2023-07-15 / J Immunol 2023 Jul;211(2):219-2282023-07-15 00:00:002024-01-16 09:10:27Efficacy of a Dual-Epitope Dendritic Cell Vaccine as Part of Combined Immunotherapy for HER2-Expressing Breast Tumors
